MX2019010994A - Metodos para tratar enfermedades y trastornos mediados por el complemento. - Google Patents

Metodos para tratar enfermedades y trastornos mediados por el complemento.

Info

Publication number
MX2019010994A
MX2019010994A MX2019010994A MX2019010994A MX2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A MX 2019010994 A MX2019010994 A MX 2019010994A
Authority
MX
Mexico
Prior art keywords
methods
antibody
individual
disorders
mediated diseases
Prior art date
Application number
MX2019010994A
Other languages
English (en)
Inventor
Nancy E Stagliano
Sandip Panicker
Graham Parry
Vlasselaer Peter Van
Original Assignee
Bioverativ Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc filed Critical Bioverativ Usa Inc
Publication of MX2019010994A publication Critical patent/MX2019010994A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente divulgación suministra métodos para tratar una enfermedad o trastorno mediados por complemento al individuo, y métodos de inhibir la activación del componente C4 del complemento en un individuo en necesidad del mismo. Los métodos comprenden administrar a un individuo un anticuerpo anti-C 1s. Los métodos también comprenden administrar un anticuerpo anti-C1s en una dosis fija, por ejemplo, 5.5 g, 6.5 g, 7.5 g. Los métodos también comprenden administrar una dosis eficaz de un anticuerpo anti-C 1 s al individuo para alcanzar un nivel de suero mínimo de anticuerpo anti-C 1 s para el efecto terapéutico.
MX2019010994A 2017-03-14 2018-03-14 Metodos para tratar enfermedades y trastornos mediados por el complemento. MX2019010994A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471190P 2017-03-14 2017-03-14
US201762553059P 2017-08-31 2017-08-31
PCT/US2018/022462 WO2018170145A1 (en) 2017-03-14 2018-03-14 Methods for treating complement-mediated diseases and disorders

Publications (1)

Publication Number Publication Date
MX2019010994A true MX2019010994A (es) 2020-12-01

Family

ID=61873979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010994A MX2019010994A (es) 2017-03-14 2018-03-14 Metodos para tratar enfermedades y trastornos mediados por el complemento.

Country Status (13)

Country Link
US (1) US20210115116A1 (es)
EP (1) EP3596121A1 (es)
JP (2) JP7293122B2 (es)
KR (1) KR20190128676A (es)
CN (1) CN110753701A (es)
AU (1) AU2018236267A1 (es)
BR (1) BR112019018950A2 (es)
CA (1) CA3055781A1 (es)
CR (1) CR20190468A (es)
IL (1) IL269174A (es)
MX (1) MX2019010994A (es)
SG (1) SG11201907583TA (es)
WO (1) WO2018170145A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US8945562B2 (en) 2012-11-02 2015-02-03 True North Therapeutics, Inc. Anti-complement C1s antibodies
LT3280440T (lt) 2015-04-06 2023-02-27 Bioverativ Usa Inc. Humanizuoti antikūnai prieš c1s ir jų panaudojimo būdai
US11161900B2 (en) 2018-12-13 2021-11-02 Argenx Bvba Antibodies that specifically bind to human complement factor C2b
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
EP4065165A1 (en) * 2019-11-26 2022-10-05 Omeros Corporation Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
FI129383B (en) * 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION
CA3187866A1 (en) 2020-08-06 2022-02-10 Jaime Morales ARIAS Inflammatory cytokines and fatigue in subject with a complement mediated disease
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
WO2023287573A2 (en) 2021-07-13 2023-01-19 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
US20240025978A1 (en) * 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US8945562B2 (en) 2012-11-02 2015-02-03 True North Therapeutics, Inc. Anti-complement C1s antibodies
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays

Also Published As

Publication number Publication date
JP7293122B2 (ja) 2023-06-19
TW201842931A (zh) 2018-12-16
JP2023071824A (ja) 2023-05-23
CN110753701A (zh) 2020-02-04
WO2018170145A1 (en) 2018-09-20
CR20190468A (es) 2019-12-17
CA3055781A1 (en) 2018-09-20
EP3596121A1 (en) 2020-01-22
US20210115116A1 (en) 2021-04-22
JP2020511469A (ja) 2020-04-16
AU2018236267A1 (en) 2019-09-26
KR20190128676A (ko) 2019-11-18
BR112019018950A2 (pt) 2020-04-22
IL269174A (en) 2019-11-28
SG11201907583TA (en) 2019-09-27

Similar Documents

Publication Publication Date Title
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
SA519400950B1 (ar) Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة
MX2023008368A (es) Uso de antagonista de il-33 o un antagonista de il-4r en la fabricacion de un medicamento para tratar enfermedades o trastornos inflamatorios.
PH12020552060A1 (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
JOP20190147A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
EA201992862A1 (ru) Назальные лекарственные формы дигидроэрготамина
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
PH12020551179A1 (en) Methods for treating mitochondrial disorder
MX2021011269A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina.
BR112021014566A2 (pt) Moduladores de gpr35
MX2021006242A (es) Formulaciones de capsula.
FR3045392B1 (fr) Dispositif pour le traitement d'un sujet par combinaison notamment de la lithotherapie, la chromotherapie, la luminotherapie et la musicotherapie
TN2019000238A1 (en) Methods for treating complement-mediated diseases and disorders
BR112019024875A2 (pt) Métodos para o tratamento da ileíte do reservatório crônica